Exosome-mediated microRNA-497 delivery for anti-cancer therapy in a microfluidic 3D lung cancer model
Related Experiment Video
Updated: Dec 30, 2025
Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
Published on: May 27, 2016
Kyeongsoo Jeong1, Yeong Jun Yu2, Jae Young You1
1Department of Bioengineering and Nano-Bioengineering, Incheon National University, Incheon 22012, Republic of Korea. wjrhee@inu.ac.kr.
Abstract:
Non-small cell lung cancer (NSCLC) is one of the leading causes of death from cancer worldwide. The delivery and controlled regulation of miRNAs via exosomes is known as a potential therapeutic approach in the treatment of cancer. In this study, human cell-derived exosomes were used as delivery vehicles for miRNAs, and we investigated their anti-tumor and anti-angiogenic effects on NSCLCs that were cultured in 2D and 3D microfluidic devices. We demonstrated that exosomes that contained miRNA-497 (miR-497) effectively suppressed tumor growth and the expression of their associated genes, i.e., yes-associated protein 1 (YAP1), hepatoma-derived growth factor (HDGF), cyclin E1 (CCNE1), and vascular endothelial growth factor-A (VEGF-A), in A549 cells. Also, the level of VEGF-A-mediated angiogenic sprouting was decreased drastically in human umbilical vein endothelial cells (HUVECs) cultured in a microfluidic device. To mimic the in vivo-like tumor microenvironment of NSCLC, A549 cells were co-cultured with HUVECs in a single device, and miR-497-loaded exosomes were delivered to both types of cells. As a result, both the tube formation of endothelial cells and the migration of tumor decreased dramatically compared to the control. This indicated that miR-497 has synergistic inhibitory effects that target tumor growth and angiogenesis, so exosome-mediated miRNA therapeutics combined with the microfluidic technology could be a predictive, cost-efficient translational tool for the development of targeted cancer therapy.
Insights
Exosomes carrying microRNA-497 (miR-497) effectively inhibited non-small cell lung cancer (NSCLC) growth and angiogenesis. This exosome-mediated miRNA therapy, combined with microfluidics, shows promise for targeted cancer treatment.
Area of Science:
- Biomedical Engineering
- Cancer Biology
- Nanotechnology
Background:
- Non-small cell lung cancer (NSCLC) remains a major global cancer mortality cause.
- Exosomes offer a promising platform for delivering therapeutic microRNAs (miRNAs) for cancer treatment.
- Microfluidic devices provide advanced models for studying cancer in controlled microenvironments.
Purpose of the Study:
- To investigate the anti-tumor and anti-angiogenic effects of miRNA-497 (miR-497) delivered via exosomes on NSCLC.
- To evaluate the efficacy of exosome-mediated miR-497 delivery in 2D and 3D microfluidic culture systems.
- To assess the potential of this approach as a translational tool for targeted cancer therapy.
Main Methods:
- Human cell-derived exosomes were loaded with miR-497.
- Exosomes were used to treat A549 NSCLC cells cultured in 2D and 3D microfluidic devices.
- Effects on tumor growth, gene expression (YAP1, HDGF, CCNE1, VEGF-A), and angiogenesis in human umbilical vein endothelial cells (HUVECs) were analyzed.
- Co-culture models of A549 and HUVECs in microfluidic devices were used to simulate the tumor microenvironment.
Main Results:
- Exosomes loaded with miR-497 significantly suppressed NSCLC tumor growth and key oncogenic gene expression (YAP1, HDGF, CCNE1, VEGF-A).
- miR-497 delivery via exosomes markedly reduced VEGF-A-mediated angiogenesis in HUVECs.
- In a co-culture microfluidic model, miR-497-loaded exosomes demonstrated synergistic inhibition of endothelial tube formation and tumor cell migration.
Conclusions:
- Exosome-mediated delivery of miR-497 exhibits potent anti-tumor and anti-angiogenic effects against NSCLC.
- Microfluidic technology combined with exosome-based miRNA therapeutics offers a predictive and cost-efficient platform for developing targeted cancer therapies.
- This integrated approach holds significant potential for advancing NSCLC treatment strategies.
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs